E-resources
-
Jerby-Arnon, Livnat; Shah, Parin; Cuoco, Michael S.; Rodman, Christopher; Su, Mei-Ju; Melms, Johannes C.; Leeson, Rachel; Kanodia, Abhay; Mei, Shaolin; Lin, Jia-Ren; Wang, Shu; Rabasha, Bokang; Liu, David; Zhang, Gao; Margolais, Claire; Ashenberg, Orr; Ott, Patrick A.; Buchbinder, Elizabeth I.; Haq, Rizwan; Hodi, F. Stephen; Boland, Genevieve M.; Sullivan, Ryan J.; Frederick, Dennie T.; Miao, Benchun; Moll, Tabea; Flaherty, Keith T.; Herlyn, Meenhard; Jenkins, Russell W.; Thummalapalli, Rohit; Kowalczyk, Monika S.; Cañadas, Israel; Schilling, Bastian; Cartwright, Adam N.R.; Luoma, Adrienne M.; Malu, Shruti; Hwu, Patrick; Bernatchez, Chantale; Forget, Marie-Andrée; Barbie, David A.; Shalek, Alex K.; Tirosh, Itay; Sorger, Peter K.; Wucherpfennig, Kai; Van Allen, Eliezer M.; Schadendorf, Dirk; Johnson, Bruce E.; Rotem, Asaf; Rozenblatt-Rosen, Orit; Garraway, Levi A.; Yoon, Charles H.; Izar, Benjamin; Regev, Aviv
Cell, 11/2018, Volume: 175, Issue: 4Journal Article
Immune checkpoint inhibitors (ICIs) produce durable responses in some melanoma patients, but many patients derive no clinical benefit, and the molecular underpinnings of such resistance remain elusive. Here, we leveraged single-cell RNA sequencing (scRNA-seq) from 33 melanoma tumors and computational analyses to interrogate malignant cell states that promote immune evasion. We identified a resistance program expressed by malignant cells that is associated with T cell exclusion and immune evasion. The program is expressed prior to immunotherapy, characterizes cold niches in situ, and predicts clinical responses to anti-PD-1 therapy in an independent cohort of 112 melanoma patients. CDK4/6-inhibition represses this program in individual malignant cells, induces senescence, and reduces melanoma tumor outgrowth in mouse models in vivo when given in combination with immunotherapy. Our study provides a high-resolution landscape of ICI-resistant cell states, identifies clinically predictive signatures, and suggests new therapeutic strategies to overcome immunotherapy resistance. Display omitted •Single-cell RNA-seq identifies an immune resistance program in malignant cells•Multiple immune resistance mechanisms are co-regulated in the program•The program predicts clinical responses to immunotherapy in melanoma patients•CDK4/6 inhibitors repress the program and may sensitize melanoma to immunotherapy Single-cell sequencing of checkpoint-inhibitor-resistant melanomas identifies predictive signatures to guide therapeutic approaches to overcome immunotherapy resistance.
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.